BEIJING, March 24, 2026 /PRNewswire/ — At a dock of a local shipyard base in Longkou City of east China, H580 ECO STAR, a dual fuel-powered vehicle carrier capable of carrying 7,000 cars, returned recently back to its berth after a four-day-long trial voyage.

The vessel built by Yantai CIMC Raffles Ocean Technology Group (CIMC Raffles Group) tested its main engine endurance, travelling speed, anchor dropping, unmanned engine room, etc.

As Jin Fujun, manager of the Longkou CIMC Raffles H580 project, introduced, the trial voyage completely fulfilled the predetermined testing goals of the large vehicle carrier.

With a length of 199.9 meters and a molded width of 38 meters, the H580 ECO STAR is the third vessel crafted by CIMC Raffles Group for Greek shipping firm Atlas Maritime with a designed travelling speed of 19 knots.

Equipped with a tailored fire protection system, the dual fuel-powered vehicle carrier can not only operate at port with zero carbon emission, but also meet requirements of green shipping given its DNV ammonia-ready and F(EV)-related standards-meeting capabilities.

As an eye-catching milestone for made-in-Longkou vessels, the H580 ECO STAR is expected to contribute to global low-carbon and green shipping.

Original link: https://en.imsilkroad.com/p/349867.html

SUZHOU, China, March 24, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN026) in combination with albumin-bound docetaxel (HB1801) and chemotherapy as adjuvant treatment for HER2-positive breast cancer (BC). Anbenitamab (KN026) is independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK).

Breast cancer is the most common malignant tumor among women in China, with the HER2-positive subtype accounting for approximately 20% to 30% of all cases. Although trastuzumab (with or without pertuzumab) combined with chemotherapy has significantly reduced the risk of recurrence, subgroup analyses from multiple clinical studies indicate that patients with HER2-positive BC who are lymph node-positive, particularly those with four or more positive lymph nodes, continue to face a high risk of recurrence. Compared with regimens containing trastuzumab alone, dual-targeted therapy combined with chemotherapy as adjuvant treatment for HER2-positive BC can further reduce the risk of recurrence, with the most pronounced benefit observed in lymph node-positive patients. Accordingly, the exploration of more effective adjuvant treatment strategies to improve long-term outcomes for this patient population is of significant clinical importance.

KN026-007 is a randomized, controlled, open-label, multicenter Phase III clinical study, which is expected to enroll approximately 1,800 patients with resectable HER2-positive BC who have histologically confirmed involvement of four or more regional lymph nodes following surgery. Eligible patients will be randomized in a 1:1 ratio, aiming to compare the efficacy and safety of Anbenitamab in combination with HB1801 and chemotherapy versus trastuzumab plus pertuzumab in combination with chemotherapy as adjuvant treatment. The primary endpoint of the study is investigator-assessed invasive disease-free survival (iDFS) . Secondary endpoints include disease-free survival (DFS), recurrence-free interval (RFI), distant recurrence-free interval (DRFI), overall survival (OS), safety, pharmacokinetics, and immunogenicity.

About Anbenitamab (KN026)

Anbenitamab (KN026) is an anti-HER2 bispecific antibody independently developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). Anbenitamab can simultaneously bind two non-overlapping epitopes of HER2, resulting in HER2 signal blockade. Through antibody-induced receptor clustering, it enhances ADCC and CDC effects while promoting the down-regulation of HER2 receptors on the cell surface.

In September 2025, the first New Drug Application (NDA) for anbenitamab injection has been accepted by the National Medical Products Administration (NMPA) for the treatment of HER2-positive gastric cancer (GC). Currently, several pivotal clinical trials of KN026 for second-line or above HER2-positive GC/gastroesophageal junction cancer (GEJ), first-line HER2-positive breast cancer (BC), neoadjuvant treatment of HER2-positive BC are being conducted.

Anbenitamab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive or low expressing GC; it has been granted Breakthrough Therapy Designation by NMPA for the treatment of patients with HER2-positive GC/GEJ who have failed first-line standard treatment.

In August 2021, the Company entered an agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), for the development and commercialization of KN026 in Mainland China. JMT-Bio was granted exclusive license rights of KN026 for the development and commercialization in the indications of BC an GC/GEJ in Mainland China (excluding Hong Kong, Macau and Taiwan).

About Docetaxel (Albumin-Bound)

Docetaxel (Albumin-Bound) for Injection (HB1801) is a product developed by CSPC using innovative technology to encapsulate docetaxel in human serum albumin. Compared with conventional docetaxel injection, this novel formulation offers several advantages:

Safety: No premedication with corticosteroids is required, and it enables high-concentration and rapid administration, thereby improving safety and patient compliance.

Efficacy: It demonstrates potent anti-tumor activity in multiple preclinical tumor models and allows higher clinical dosing to further improve therapeutic effects.

Data from multiple clinical trials have consistently shown that HB1801 exhibited favorable efficacy and safety profiles, achieving the goal of reduced toxicity and enhanced efficacy. Several phase III trials of HB1801 in patients with breast cancer and gastric cancer are ongoing.

About Alphamab Oncology

Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.

One product has received market approval: Envafolimab (KN035, brand name: 恩维达^®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Five bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide.

CFA Institute survey of investors across global markets shows strong digital engagement, demand for personalization, and evolving definitions of trust

SINGAPORE, March 24, 2026 /PRNewswire/ — CFA Institute, the global association of investment professionals, today released new research demonstrating how Gen Z and millennial mass-affluent, high-net-worth (HNW) and very-high-net-worth (VHNW) investors are redefining the future of private wealth management.

As trillions of dollars pass to younger generations in the Great Wealth Transfer, the research titled, Next-Gen Investors: A Guide for Wealth Managers and Financial Advisers, explores how behaviors and expectations of Gen Z and millennial investors differ from Gen X and Baby Boomer investors — and what this means for the future of financial advice and wealth management. 

Drawing on a survey of more than 2,400 mass affluent, HNW, and VHNW investors in Canada, India, Singapore, the United Arab Emirates, the United Kingdom, and the United States, the research finds strong demand for advice among young investors, and offers data-supported insights for advisers and wealth managers to succeed with the next generation of wealth management clients. 

Findings from the research reveals that in Singapore, around 70 percent of young investors expect to receive an inheritance. They also report the highest likelihood of holding ETF investments (50 percent), compared with 29 percent for Singaporean Gen X and Baby Boomer investors.

Cindy Tan, CFA, CA (Singapore), President, CFA Society Singapore, comments:

“It is encouraging that the majority of Singapore’s young investors say they feel confident about investing and reaching their financial goals. Notably, the top three asset classes they plan to own are individual stocks, ETFs and cryptocurrency. Singaporean Gen Z and millennial investors also heavily use mobile and digital communication channels when engaging with advisors, with high use of messaging Apps and text messaging relative to investors in other markets.”

“These trends signal growing demand for advisory models that blend professional expertise with sophisticated product offerings, urging wealth managers to rethink how they engage next-gen clients in an evolving wealth landscape. We look forward to exploring these themes with industry leaders at CFA Society Singapore’s Private Wealth Symposium later this month.” 

Rhodri Preece, CFA, Senior Head of Research at CFA Institute, adds:

“Gen Z and millennial high-net-worth investors are reshaping private wealth management in fundamental ways. Their desire for holistic advice, product preferences, and expectations regarding the frequency and modes of communication differ meaningfully from their older peers and the models that shaped today’s industry. They expect real-time access to information, frequent digital engagement, more investment options and access, and guidance that integrates life goals, behavioral discipline, and long-term investment strategies.”

Genevieve Hayman, PhD, Senior Researcher, CFA Institute, and co-author of the research comments:

“Our survey data show that wealthy Gen Z and millennial investors are not turning away from professional advice, but they are redefining it. They expect active participation in financial planning and want collaborative, hybrid advice models that combine human expertise with technology-enabled personalization.” 

“To serve this next generation of clients, wealth management and advisory services must evolve from an interpersonal-driven model to one that can scale personalization while preserving trust. Technology, including AI, will be essential to delivering that experience.”   

Key Global Insights from the Survey:

• Strong Demand for Financial Advice:
  Over 90 percent of wealthy Gen Z and millennial investors surveyed report using some form of paid financial advice, including traditional advisers, robo-advisers, accountants, or lawyers. Gen Z investors are more likely to receive financial advice through workplace plans or robo-advisers. Millennials are most likely to use traditional advisers. Nearly 70 percent of young investors surveyed who engage a paid adviser interact with their adviser at least monthly.
• Innovation, Market Trends, and FOMO
  More than half of young HNW and VHNW investors (55 percent) report making investment decisions driven by “fear of missing out” (FOMO), particularly in emerging asset classes such as cryptocurrency. They seek advisers who can contextualize new developments and be a strategic, forward-looking partner, balancing innovation with prudent advice.
• Trust is Enhanced Through Performance Measures and Data Security
  “Trustworthy” and “ethical” remain the most important qualities when selecting an adviser, but what defines trust differs across generations. Young investors define trust through measurable behavior, professional competence, and digital integrity. They value transparency, credentials, and cybersecurity alongside empathy and cost clarity.
• Use of Digital Resources is Strong, but Advisers Remain the Most Trusted Source
  Young investors learn from a wide range of online sources and about one-third have used generative AI for financial education. Yet human advisers remain the single-most-trusted source of investment guidance. Millennials are the most likely to access a paid professional adviser through an investment firm, wealth manager, or family office (58 percent). Millennials also show strong appetite for advisory services across both human and robo-advisory formats. Gen Z are most likely to access robo-investment advice only (43 percent).

About CFA Institute
As the global association of investment professionals, CFA Institute sets the standard for professional excellence and credentials. We champion ethical behavior in investment markets and serve as the leading source of learning and research for the investment industry. We believe in fostering an environment where investors’ interests come first, markets function at their best, and economies grow. With more than 200,000 charterholders worldwide across 160 markets, CFA Institute has 9 offices and 157 local societies. Find us at www.cfainstitute.org or follow us on LinkedIn, and subscribe on YouTube.  

About CFA Society Singapore
CFA Society Singapore is part of a worldwide network of CFA Institute member societies that lead the investment profession globally by promoting the highest standards of ethics, education, and professional excellence for the ultimate benefit of society. It represents the interests of more than 4,000 investment professionals through advocacy, education, events, and professional development. Visit: https://cfasocietysingapore.org.

Bringing to Life How Schools, Homes, and Communities Are Changing Across Japan Through Real Insights from the Field

TOKYO, March 24, 2026 /PRNewswire/ — LEIFRAS Co., Ltd. (Nasdaq: LFS) (the “Company” or “Leifras”), a sports and social business company dedicated to youth sports and community engagement, today announced the release of two business introduction videos highlighting the real-world implementation and impact of its school club support business and after-school daycare service business, the core pillars of the Company’s social business. The videos illustrate the Company’s role in addressing pressing social challenges in Japan, including long working hours for teachers and the increasing demand for developmental support for children, while showcasing the sustainable operational framework behind Leifras’ initiatives through stakeholder interviews and real footage from the field.

Background of the Release: Unraveling a Complex System through Video
As part of its efforts to enhance children’s welfare, the Japanese government is promoting “club activity reform” to facilitate student participation, while supporting the development of “after-school daycare services” for children with disabilities. The implementation of these initiatives requires specialized know-how and complex system design. To help visualize the school environment following the transition of club activities to local communities, which can be difficult to convey through written materials alone, the Company produced documentary-style videos that closely follow the programs in action at actual operating sites.

Business Video No. 1: School Club Support Business
Theme: “Building Sustainable Infrastructure Toward the 2026 Reform Implementation Period”

• Japanese version: https://youtu.be/tfBx63xDVes
• English version: https://youtu.be/14oO4IdMyVo

The video explains how the Company is transforming school club activities with an eye toward the “reform implementation period” beginning in 2026, as set by the Ministry of Education, Culture, Sports, Science and Technology of Japan.

• Beneficiary payment model in practice at Chiyoda Junior and Senior High School: The video features a school that introduced a beneficiary payment model under which parents have covered the costs since April 2025. It captures the perspective of teachers on the change, including one who shared, “We now have time for meetings and to think about the students’ futures,” offering a concrete look at what reformed club activities can look like.
• Dedicated school club activity managers: Rather than simply dispatching instructors, the Company assigns a dedicated manager who serves as a liaison among schools, parents, and the community. The role functions as a coordinating infrastructure within the system that helps identify optimal solutions for each region.

Business Video No. 2: After-school Daycare Service – “LEIF”
Theme: “The Mechanism of ‘Sociality’ and ‘Independence’ Developed Through Soccer”

• Japanese version: https://youtu.be/JLN4Qjc0EX0
• English version: https://youtu.be/pzxk2vbp6lQ

The video highlights the “sports therapy” aspect of LEIF, the after-school daycare service operated by Leifras.

• A unique approach combining sports and therapeutic education: Unlike typical daycare services, the Company uses soccer as a teaching medium to demonstrate how children can learn the rules of group interaction and cooperation while having fun.
• Building self-esteem and peer support: The video captures a moment when a child who previously struggled to express emotions scores a goal and high-fives friends, as well as the process of change (peer support) in which older children begin to look after younger ones.
• Parent testimonials: Parents share firsthand accounts of the program’s impact, such as “The fact that they incorporated sports, especially soccer, into their therapeutic education was quite unusual. I was attracted to that and immediately chose LEIF” and “children’s self-esteem has grown.”

Future Outlook
The Company plans to use these videos in proposals to local governments and boards of education and as informational materials for parents, helping enhance transparency and trust in its services. Guided by its philosophy of “Changing and designing sports,” the Company will continue to provide real insights from the field and contribute to improving Japan’s education and welfare environment.

About LEIFRAS Co., Ltd.
Headquartered in Tokyo, Leifras is a sports and social business company dedicated to youth sports and community engagement. The Company primarily provides services related to the organization and operations of sports schools and sports events for children. As of December 31, 2024, Leifras was recognized as one of Japan’s largest operators of children’s sports schools in terms of both membership and facilities by Tokyo Shoko Research. The Company’s approach to sports education emphasizes the development of non-cognitive skills, following the teaching principle “acknowledge, praise, encourage, and motivate.” The holistic approach that integrates physical and mental development sets Leifras apart in the industry. Building upon deep experience and know-how in sports education, Leifras also operates a robust social business sector, dispatching sports coaches to meet various community needs with the aim to promote physical health, social inclusion, and community well-being across different demographics.

For more information, please visit the Company’s website: https://ir.leifras.co.jp/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the registration statement filed with the U.S. Securities and Exchange Commission (the “SEC”). Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the registration statement and other filings with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

For more information, please contact:

LEIFRAS Co., Ltd.
Investor Relations Department
Email: IR@leifras.co.jp

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com